Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives
| Autor: | Hak-Kim Chan, Tiffanie Daisy Sugianto |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Drug
medicine.medical_specialty media_common.quotation_subject Pharmaceutical Science 02 engineering and technology medicine.disease_cause 03 medical and health sciences Drug Delivery Systems 0302 clinical medicine Fibrosis Administration Inhalation Humans Medicine Adverse effect Intensive care medicine media_common Clinical Trials as Topic Bronchiectasis Respiratory tract infections business.industry Pseudomonas aeruginosa Bacterial Infections 021001 nanoscience & nanotechnology medicine.disease Anti-Bacterial Agents 030228 respiratory system Chronic Disease Drug delivery Sputum medicine.symptom 0210 nano-technology business |
| Zdroj: | Expert Opinion on Drug Delivery. 13:7-22 |
| ISSN: | 1744-7593 1742-5247 |
| DOI: | 10.1517/17425247.2015.1078309 |
| Popis: | Non-cystic fibrosis bronchiectasis (NCFB) is a chronic, progressive, suppurative lung disease characterized by permanent dilatation of bronchial subdivisions, which further causes accumulation of sputum and bacterial infections. The advent of inhaled antibiotics over the past two decades has been expected to effectively attenuate the problem of chronic bacterial infections in CF and NCFB subjects with higher, local drug concentrations and minimal systemic side effects.This review summarizes and evaluates current clinical evidence of efficacy and adverse effects of inhaled antibiotics in NCFB, as well as ongoing preclinical and clinical studies, followed by a discussion of issues and challenges in clinical practice and drug delivery strategies, together with future research directions.The evidence base of the clinical efficacy of inhaled antibiotics in NCFB is limited and the degrees of reported clinical benefits have been modest and conflicting. Challenges surrounding inhaled antibiotics application and development include the lack of knowledge of disease factors and optimum management strategies, unreceptive lung pathophysiology and the lack of factors that support compliance and tolerability. Nonetheless, research continues to give birth to new clinical findings and novel formulations such as combination antibiotics and sustained-release formulations, which add great value to the development of efficacious, safe and convenient inhalable antibiotics of the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|